Insights provides context and perspective about key pharmacy trends and issues

Paying for Drugs Based on Outcomes
Cost Management
Value-based management seeks go beyond a static, pre-set price tag to uncover true value for drugs and better health for patients. More
Briefing
Specialty
Blockbuster cancer drug Zytiga may become first-line treatment for patients with metastatic, castration-resistant cancer, greatly expanding its market and cost impact. More
Feature
Drug Pipeline
Key drugs to watch for in the specialty pharmacy pipeline Q3-Q4 2017 More
Specialty Report
Pharmacy Innovation
New research in JAMA Cardiology shows that simply putting patients in an ACO does not improve adherence. Utilizing proven PBM interventions may help. More
Commentary
Aligning Drug Prices with Value
Cost Management
The current model of static, manufacturer-set drug prices is simply unsustainable. Value-based management approaches attempt to incentivize quality and efficacy. More
Briefing
Government Programs and Services
Despite lack of consistent national standards, payors can earn meaningful incentives for improvements to Medicaid quality measures. More
Briefing
Cost Management
New utilization management criteria ensure appropriate use of PCSK9 inhibitors, which can help lower bad cholesterol levels, but are significantly more expensive first-line therapies More
Briefing
Government Programs and Services
Despite the lack of consistent, national quality measures, plans can achieve meaningful financial rewards by through improvements in pharmacy care. More
Briefing
Public Policy
A focus on prioritizing generic review and fostering competition could help in the battle against sky-rocketing prescription drug costs. More
Commentary
Specialty
Wearable health trackers, secure texting, and new biomarker technology allow for increased patient engagement and better health outcomes. More
Briefing